Infinimmune secured $75 million in Series A funding to develop antibody candidates for atopic dermatitis, targeting IL-22 with IFX-101 and IL-13 with IFX-201. The financing was positioned as fuel for two programs expected to enter the clinic in 2027, backed by Regeneron Ventures and Playground Global and with additional investor participation. The company’s strategy focuses on improved durability and potency versus existing systemic biologics in eczema, a crowded therapeutic area with multiple approved injectable options. Infinimmune’s lead claims include IL-22 being an “underestimated” component of eczema biology with no approved biologic specifically hitting that axis. The raise signals continued willingness from late-stage venture platforms to fund next-generation immunology mechanisms for large indication markets, particularly those where patients may cycle between therapies. Market impact: the new capital supports early clinical development and de-risks manufacturability timelines for two differentiated antibody programs competing with established IL-4/IL-13 and IL-13-directed offerings.